Tirzepatide, the main ingredient for Eli Lilly’s Mounjaro and Zepbound, omitted the presence of metabolic dysfunction-associated steatohepatitis in a phase 2 study, the drugmaker said June 8. The trial results could precede another indication for the popular drugs.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
